Fig 2: Ovarian cancer TAMs highly express FRß and are targeted by human FRß CAR-T cells.a hFRß expression in TAMs obtained from the ascites of ovarian cancer patients as assessed by flow cytometry. Representative histogram (gray—isotype, red—anti-hFRß, left panel) and mean frequency of FRß+ TAMs (defined as live, CD45+CD11b+CD14+ cells, right panel) ± SD are shown (n = 7 ascites biospecimens). b Representative flow plots showing coexpression of hFRß (X-axis) and the surface markers CD206 (left panel) and CD163 (right panel, Y-axis) in ovarian cancer patient TAMs. Overnight cocultures of hFRß CAR, hCD19 CAR, or UTD T cells with CD11b+ cells isolated from the ascites of ovarian cancer patients were established at a 1:1 E:T ratio. c Levels of secreted hIFN-? as detected by ELISA in the supernatants. P values by a two-way ANOVA with Tukey’s multiple comparison test are indicated. d Real-time cytotoxicity assay performed using xCelligence technology. c, d Representative data from one of three different patients is shown as mean ± SD of triplicates. e Progression-free survival curves for human ovarian cancer patients with high (red) or low (black) expression of FOLR2 (gene encoding for FRß) at different clinical stages. The clinical outcome data were retrieved from the Kaplan–Meier plotter database. N indicates the number of patients included in the analysis for each stage. P values by a log-rank Mantel–Cox test are indicated. EOC epithelial ovarian cancer. Source data are provided in the Source Data file.